About Us - CiRC Biosciences

CiRC Biosciences

CiRC is in pre-clinical development of a potential cell therapy treatment for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

Our proprietary technology, chemically induced photoreceptor-like cells (CiPCs) to treat RP, received U.S. FDA Orphan Drug Designation.

We are a portfolio company of Paragon Biosciences.

CiRC Biosciences

CiRC is in pre-clinical development of a potential cell therapy treatment for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

Our proprietary technology, chemically induced photoreceptor-like cells (CIPSs) to treat RP, received U.S. FDA Oprhan Drug Designation.

We are a portfolio company of Paragon Biosciences.

Retinitis

Pigmentosa

Approximately 300,000 people in the U.S. and Europe are living with RP. Worldwide, RP is estimated to affect 2 million people.

RP is a genetic condition that can be caused by more than 70 gene mutations. RP negatively affects the retina as photoreceptors degenerate. This can lead to irreversible vision loss overtime.

Dry Age-Related
Macular Degeneration

Dry Age-Related

Macular Degeneration

An estimated 1.5 million people in the U.S. and 5 million people globally have dry age-related macular degeneration (Dry AMD), making it the leading cause of irreversible vision loss in people over the age of 65. With Dry AMD, support cells called retinal pigment epithelium (RPE) degenerate, causing photoreceptors to die.

Retinitis Pigmentosa

CiRC Biosciences

CiRC is in pre-clinical development of a potential cell therapy treatment for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

Our proprietary technology, chemically induced photoreceptor-like cells (CiPCs) to treat RP, received U.S. FDA Orphan Drug Designation.

We are a portfolio company of Paragon Biosciences.

Retinitis

Pigmentosa

Approximately 300,000 people in the U.S. and Europe are living with RP. Worldwide, RP is estimated to affect 2 million people.

RP is a genetic condition that can be caused by more than 70 gene mutations. RP negatively affects the retina as photoreceptors degenerate. This can lead to irreversible vision loss overtime.

Dry Age-Related
Macular Degeneration

Dry Age-Related

Macular

Degeneration

An estimated 1.5 million people in the
U.S. and 5 million people globally have dry age-related macular degeneration (Dry AMD), making it the leading cause of irreversible vision loss in people over the age of 65. With Dry AMD, support cells called retinal pigment epithelium (RPE) degenerate, causing photoreceptors to die.